Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | NQO2 | P16083 | 4/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14286694 | 0.86 | NPC1 (0.42) | KIF11NPC1RAB9AHDAC1HDAC8 | |
| SCHEMBL17825591 | 0.81 | KIF11 (0.46) | KIF11MTNR1AMTNR1BNQO2 | |
| SCHEMBL7147416 | 0.80 | KIF11 (0.50) | KIF11MEN1KMT2A | |
| SCHEMBL7144169 | 0.80 | KIF11 (0.50) | KIF11MEN1KMT2A | |
| SCHEMBL14286735 | 0.78 | NPC1 (0.40) | KIF11NPC1RAB9AHDAC1HDAC8 | |
| SCHEMBL7147740 | 0.75 | KIF11 (0.61) | KIF11MEN1KMT2A | |
| SCHEMBL14286737 | 0.74 | KIF11 (0.37) | KIF11NPC1RAB9AHDAC1HDAC8 | |
| SCHEMBL8843202 | 0.73 | MTNR1A (0.39) | KIF11NPC1RAB9AMTNR1AMTNR1B | |
| SCHEMBL3611740 | 0.73 | HDAC1 (0.39) | NPC1RAB9AHDAC1HDAC8MTNR1A | |
| SCHEMBL3605593 | 0.73 | NAMPT (0.39) | NPC1RAB9AHDAC1HDAC8MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | KIF11 1071/4885NPC1 242/4885RAB9A 1685/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | KIF11 1071/4885NPC1 242/4885RAB9A 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.